Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Repository of the University of Ljubljana
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Advanced
New in RUL
About RUL
In numbers
Help
Sign in
Details
Secondary findings in hereditary cancer genes after germline genetic testing : systematic review of literature
ID
Avsec, Eva
(
Author
),
ID
Blatnik, Ana
(
Author
),
ID
Krajc, Mateja
(
Author
)
PDF - Presentation file,
Download
(1,35 MB)
MD5: 60E37D6E4F1156EF3FD6429059022A99
URL - Source URL, Visit
https://link.springer.com/article/10.1007/s00439-025-02746-w
Image galllery
Abstract
In the last decade the increasing use of germline genetic testing has led to frequent discoveries of secondary findings (SF) in hereditary cancer (HC) genes. Disclosure and clinical management of such findings are still not clearly defined and raise many ethical, clinical, and practical questions. This systematic review is focused on frequency of reported SF in HC genes across different populations as well as summarizing current guidelines, recommendations, and actual clinical practice about reporting and managing SF in HC genes. A systematic literature search according to the PRISMA guidelines was performed on the electronic database PubMed from inception to June 2024. 30 research papers involving almost 150,000 patients were reviewed. The reported frequencies of SF in HC genes varied between 0.4 and 3.1%. The majority of patients agreed to receive SF for medically actionable genes. Management and surveillance of patients after disclosure of SF in HC genes were rarely reported, but the limited data show no regret of receiving such results as well as diagnoses of early-stage cancer in patients participating in recommended surveillance programs related to SF. A substantial number of carriers of highly penetrant pathogenic variants in HC genes is discovered by reporting SF after germline genetic testing with next-generation sequencing. Additional information about the impact of SF disclosure on individuals and health care systems is needed to optimize the integration of SF into clinical care.
Language:
English
Keywords:
hereditary cancer
,
genetic testing
,
systematic review
Work type:
Article
Typology:
1.02 - Review Article
Organization:
MF - Faculty of Medicine
Publication status:
Published
Publication version:
Version of Record
Year:
2025
Number of pages:
Str. 595–604
Numbering:
Vol. 144, iss. 6
PID:
20.500.12556/RUL-178482
UDC:
616-07
ISSN on article:
0340-6717
DOI:
10.1007/s00439-025-02746-w
COBISS.SI-ID:
235578627
Publication date in RUL:
28.01.2026
Views:
327
Downloads:
129
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
Human genetics
Shortened title:
Hum. genet.
Publisher:
Springer Nature
ISSN:
0340-6717
COBISS.SI-ID:
1513999
Licences
License:
CC BY 4.0, Creative Commons Attribution 4.0 International
Link:
http://creativecommons.org/licenses/by/4.0/
Description:
This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Secondary language
Language:
Slovenian
Keywords:
dedni raki
,
genetski testi
,
sistematični pregled
Projects
Funder:
ARRS - Slovenian Research Agency
Project number:
P3-0289
Name:
Značilnosti malignih neoplazem, pomembne za diagnozo ter napoved poteka bolezni in izida zdravljenja
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back